Nutrition 21
This article was originally published in The Tan Sheet
Executive Summary
Ingredient supplier's $716,000 fourth quarter net income reflects positive impact of cost savings in SG&A, renewed focus on R&D efforts for core businesses, firm says. Full year net income fell 84% to $1.1 mil. Results reflect Chromax chromium picolinate price adjustments, Q2 restructuring charges, partially offset by positive impact of favorable settlements of patent-infringement lawsuits, initial licensing fees for nisin, lysostaphin technologies, Nutrition 21 reports